Fulcrum Capital LLC lowered its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 20.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 615 shares of the company’s stock after selling 160 shares during the quarter. Fulcrum Capital LLC’s holdings in IDEXX Laboratories were worth $311,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Riverview Trust Co bought a new stake in shares of IDEXX Laboratories during the first quarter worth about $26,000. Crewe Advisors LLC acquired a new position in IDEXX Laboratories during the 1st quarter valued at about $26,000. Ridgewood Investments LLC bought a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $27,000. Institutional & Family Asset Management LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter worth approximately $28,000. Finally, Strategic Investment Solutions Inc. IL bought a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $36,000. Institutional investors own 87.84% of the company’s stock.
IDEXX Laboratories Stock Performance
Shares of IDXX stock opened at $457.90 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. The firm has a market cap of $37.82 billion, a price-to-earnings ratio of 44.33, a P/E/G ratio of 4.14 and a beta of 1.33. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The firm’s 50-day simple moving average is $486.11 and its two-hundred day simple moving average is $490.23.
Wall Street Analysts Forecast Growth
IDXX has been the subject of several recent research reports. Piper Sandler decreased their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. JPMorgan Chase & Co. reduced their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. BTIG Research began coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price for the company. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Finally, Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $574.13.
Read Our Latest Stock Analysis on IDEXX Laboratories
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Articles
- Five stocks we like better than IDEXX Laboratories
- Where to Find Earnings Call Transcripts
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- The 3 Best Fintech Stocks to Buy Now
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How to Use the MarketBeat Excel Dividend Calculator
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.